By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline is betting on a new vaccine technology based on chimpanzee viruses by acquiring Swiss-based Okairos for 250 million euros ($321 million) - the latest bolt-on biotech buy by a big drugmaker. Britain's largest pharmaceuticals group said on Wednesday that the privately owned company's know-how was expected to play an important role in GSK's development of vaccines to both prevent and treat diseases. Okairos was spun out from Merck & Co in 2007 and has laboratories in Rome and Naples, with headquarters in Basel. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment